What ReCor Medical does

ReCor Medical Inc., founded in 2009 and headquartered in Palo Alto, California, is a medical technology company that has developed the Paradise™ Ultrasound Renal Denervation (uRDN) system — a minimally invasive, catheter-based device that delivers ultrasound energy to ablate renal nerves, paired with proprietary hydrocooling technology designed to protect the arterial wall during treatment. The Paradise system targets patients with drug-resistant or uncontrolled hypertension whose blood pressure remains elevated despite lifestyle changes and multiple antihypertensive medications, a population representing roughly one-third of the more than one billion people globally affected by hypertension. The device received FDA clearance in November 2023, and the company has subsequently secured CMS National Coverage Determination in the United States (October 2025) and Japan's National Health Insurance coverage (March 2026) for the procedure. ReCor operates as a wholly owned subsidiary of Otsuka Medical Devices and co-promotes Paradise in Japan with Otsuka Pharmaceutical, leveraging established cardiovascular and renal commercial channels. The company generates revenue through one-time hardware sales of the Paradise system to hospitals and interventional cardiology departments under enterprise field sales contracts, with recurring revenue potential from repeat procedures and consumables; detailed pricing is not publicly disclosed and is negotiated through hospital procurement processes. Ongoing post-market GPS Registry studies in the EU, UK, and US, alongside the RADIANCE trial program, are generating long-term real-world clinical evidence (19.6 mmHg reduction at six months; 15.7 mmHg reduction sustained at 24 months) to support broader physician adoption and payer coverage.

Name

ReCor Medical

Legal name

Recor Medical Inc.

Website

https://recormedical.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

251–500 employees

Short description

ReCor Medical develops the Paradise™ Ultrasound Renal Denervation system, a catheter-based device for treating drug-resistant hypertension. The wholly owned Otsuka Medical Devices subsidiary sells it via hospital field sales and co-promotion with Otsuka Pharmaceutical in Japan.

Ownership category

akta.pro rank

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Paradise uRDN System Sales: Recor Medical generates revenue through the sale of its Paradise Ultrasound Renal Denervation system to hospitals and healthcare facilities. The system is covered by Medicare in the US following CMS National Coverage Determination and by Japan's National Health Insurance system. As a medical device with FDA approval, the revenue model is one-time hardware sales with potential for recurring revenue through repeat procedures and consumables.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

ReCor Medical develops and commercializes the Paradise™ Ultrasound Renal Denervation (uRDN) System, a minimally invasive catheter-based medical device that uses ultrasound energy to ablate overactive renal nerves and reduce blood pressure in patients with drug-resistant hypertension. The Paradise system incorporates proprietary hydrocooling technology to protect the renal artery wall during ablation and is sold as a generator plus single-use catheter to hospitals and interventional cardiology departments. The product is FDA approved (November 2023), CMS Medicare covered in the US, and covered under Japan's National Health Insurance (effective March 2026).

Product overview

ReCor Medical offers a single core product: the Paradise™ Ultrasound Renal Denervation (uRDN) System. This FDA-approved medical device provides a minimally invasive treatment option for patients with drug-resistant hypertension, using targeted ultrasound energy to reduce overactive renal nerve activity. The system received regulatory clearance in November 2023 and is now commercially available in the US (with Medicare coverage) and Japan, with ongoing post-market clinical studies including the GPS Registry in the EU, UK, and US.

Differentiator

Problem solved

Functional benefit

Brands

• Paradise™: Paradise™ Ultrasound Renal Denervation (uRDN) system - an FDA-approved device for treating drug-resistant hypertension using ultrasound technology with hydrocooling.

Products and services

• Paradise™ Ultrasound Renal Denervation (uRDN) System FDA-approved, minimally invasive catheter-based ultrasound renal denervation system indicated for patients whose blood pressure remains uncontrolled despite lifestyle changes and multiple antihypertensive medications. The system uses ultrasound energy to ablate renal nerves near the kidneys and includes proprietary hydrocooling to protect the renal artery wall during treatment. It is sold to hospitals and interventional cardiology departments in the US (with Medicare coverage), EU, UK, and Japan (under National Health Insurance).

Quantifiable outcome

• 19.6 mmHg reduction in systolic blood pressure at 6 months (GPS Registry)
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Otsuka PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 1 March 2026Otsuka Pharmaceutical and Otsuka Medical Devices co-promote the Paradise uRDN system in Japan. Otsuka Pharmaceutical brings cardiovascular and renal expertise to leverage distribution through Japan's National Health Insurance system. This marks Japan's first introduction of ultrasound renal denervation therapy.
• Otsuka Medical DevicescoreStrategic or Co-development Partner · 1 November 2023Recor Medical is a wholly owned subsidiary of Otsuka Medical Devices, a Japan-based medical device company. This parent-subsidiary relationship provides strategic oversight, capital support, and access to Otsuka's global medical device infrastructure and resources.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Medtronic: Medtronic's Symplicity Spyral renal denervation system is the most direct competitor to ReCor's Paradise uRDN. Both target drug-resistant hypertension via percutaneous catheter ablation of renal nerves, though Medtronic uses radiofrequency while ReCor uses ultrasound. They compete for the same interventional cardiology hospital accounts and the same patient population.
• SoniVie: SoniVie is developing the TIVUS intravascular ultrasound-based renal denervation system, an emerging direct competitor in the same RDN category as ReCor's Paradise. Both companies use ultrasound energy to ablate renal nerves, making SoniVie the closest technology analog and a head-to-head competitor as it advances toward approval.

Emerging players

• Ablative Solutions: Ablative Solutions is pursuing catheter-based renal denervation via its Peregrine System, which uses a chemical ablation approach rather than ultrasound. It targets the same drug-resistant hypertension patient population as ReCor and represents a category competitor in the renal denervation therapy space.
• Silk Road Medical: Silk Road Medical pioneered transcarotid artery revascularization (TCAR) and sells a novel catheter-based procedure to vascular specialists. Like ReCor, it is a smaller medical device company commercializing a paradigm-shifting catheter-based intervention through specialty physician channels.
• Shockwave Medical: Shockwave Medical developed intravascular lithotripsy (IVL) for treating calcified arterial disease, a catheter-based interventional technology commercialized through the same interventional cardiology and vascular surgery call points as ReCor's Paradise uRDN. Its rapid commercial scaling illustrates the upside of novel catheter-based therapies.

Broad incumbents

• Boston Scientific: Boston Scientific is a major interventional cardiology and peripheral vascular device manufacturer whose products (catheters, guidewires, vascular imaging) are used in the same cath-lab procedures where ReCor's Paradise uRDN is deployed. While not an RDN competitor, it shares the same hospital call points and interventional cardiology customers.
• Abbott: Abbott is a global leader in interventional cardiology, vascular intervention, and structural heart devices, with established relationships at the same hospitals and interventional cardiology departments ReCor targets. It represents a broad incumbent that could enter or expand in adjacent hypertension device categories.
• Penumbra: Penumbra develops catheter-based vascular intervention devices (notably thrombectomy systems) sold to the same interventional cardiology and vascular surgery hospital customers ReCor targets. While focused on stroke and peripheral vascular disease, its commercial footprint and cath-lab relationships make it a relevant broader-incumbent peer.
• Edwards Lifesciences: Edwards Lifesciences is a leading cardiovascular device company focused on structural heart and critical care. It sells to the same interventional cardiology and cardiac surgery accounts where ReCor deploys Paradise uRDN, and represents a potential adjacent incumbent if it expands into hypertension device therapy.
• Recor Medical Inc. (Otsuka internal) - n/a; including Johnson & Johnson (Cordis): Johnson & Johnson's Cordis franchise supplies interventional cardiology catheter and vascular intervention products to the same hospital customers ReCor targets. As a global medical device incumbent with established cath-lab relationships, it represents a broader competitive presence in the procedural channels where Paradise uRDN is sold.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/radiance_htn
• Facebookfacebook.com/radiancehtn
• LinkedInlinkedin.com/company/recor-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ReCor Medical